nach oben

Drugs & Aging

Erschienen in:

01.12.2014 | Leading Article

Topical Analgesics for Neuropathic Pain in the Elderly: Current and Future Prospects

verfasst von: Jana Sawynok

Erschienen in: Drugs & Aging | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Neuropathic pain (NeP) is a significant medical and socioeconomic burden with limited therapeutic options. Elderly patients exhibit a higher incidence of several NeP conditions and pose a particular challenge due to age-related pharmacokinetic and pharmacodynamic issues, comorbid conditions, and polypharmacy, as well as frailty and cognitive decline. Topical analgesics are of interest because of their comparable efficacy to oral agents, good tolerability and safety, and potential to be add-on therapies to oral treatments. In recent years, two topical formulations for NeP have been approved (5 % lidocaine medicated plaster, 8 % capsaicin patch) but are not available in all countries. There are controlled trials and a growing body of open-label reports on their use in clinical care. Some studies provide a post hoc analysis of data in relation to older age (≥65 years), which is useful. The body of evidence relating to topical investigational agents is growing and involves controlled trials as well as individual cases. The largest single body of information is for topical ketamine, administered either alone or combined with other agents (particularly amitriptyline), and some large randomized controlled trials report efficacy. Other large trials involve topical clonidine and further ketamine combinations. Compounding analgesics involves challenges, including uncertain composition (two to five ingredients are used) and concentrations (range 0.5–5 %), as well as the heterogeneity of data that support choices. Nevertheless, case reports and acceptable response rates in larger cohorts are intriguing, and this area merits further investigation in controlled settings as well as continued documentation of clinical experiences.

Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain. Redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.PubMedCrossRef

Baron R. Mechanisms of disease: neuropathic pain—a clinical perspective. Nat Clin Pract Neurol. 2006;2(2):95–106.PubMedCrossRef

Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807–19.PubMedCrossRef

Von Hehn CA, Caron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron. 2012;73(4):638–52.CrossRef

Truini A, Garcia-Larrea L, Cruccu G. Reappraising neuropathic pain in humans—how symptoms help disclose mechanisms. Nat Neurol. 2013;9(10):572–82.CrossRef

Barkin RL. The pharmacology of topical analgesics. Postgrad Med. 2013;125(4 suppl 1):7–18.PubMed

Argoff CE. Topical analgesics in the management of acute and chronic pain. Mayo Clin Proc. 2013;88(2):195–205.PubMedCrossRef

Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 Recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip and knee. Arthritis Care Res. 2012;64(4):465–74.CrossRef

Balmaceda CM. Evolving guidelines in the use of topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. BMC Musculoskeletal Disord. 2014; 15:27 (5 pages).

10.

Argoff CE, Gloth FM. Topical nonsteroidal anti-inflammatory drugs for management of osteoarthritis in long-term care patients. Ther Clin Risk Manag. 2011;7:393–9.PubMedCentralPubMedCrossRef

11.

Peniston JH, Gold MS, Wieman MS, et al. Long-term tolerability of topical diclofenac sodium 1 % gel for osteoarthritis in seniors and patients with comorbidities. Clin Interv Aging. 2012;7:517–23.PubMedCentralPubMedCrossRef

12.

Sawynok J. Topical analgesics for neuropathic pain: preclinical exploration, clinical validation, future development. Eur J Pain. 2014;18(4):465–81.PubMedCrossRef

13.

Zur E. Topical treatment of neuropathic pain using compounded medications. Clin J Pain. 2014;30(1):73–91.PubMedCrossRef

14.

Van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654–62.PubMedCrossRef

15.

Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep. 2012;16(3):191–8.PubMedCrossRef

16.

Torrance N, Smith BH, Bennett MI, et al. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7(4):281–9.PubMedCrossRef

17.

Gore M, Dukes E, Rowbotham DJ, et al. Clinical characteristics and pain management among patients with painful peripheral neuropathic disorders in general practice settings. Eur J Pain. 2007;11(6):652–64.PubMedCrossRef

18.

Bouhassira D, Lantéri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380–7.PubMedCrossRef

19.

Gajria C, Murray J, Birger R, et al. Identification of patients with neuropathic pain using electronic primary care records. Inform Prim Care. 2011;19(2):83–90.PubMed

20.

De Moraes Vieira EB, Santos Garcia JB, Moura da Silva AA, et al. Prevalence, characteristics, and factors associated with chronic pain with and without neuropathic characteristics in São Luís, Brazil. J Pain Symptom Manag. 2012;44(2):239–51.CrossRef

21.

Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68(15):1178–82.PubMedCrossRef

22.

O’Connor AB. Neuropathic pain: a review of the quality-of-life impact, costs, and cost effectiveness of therapy. Pharmacoeconomics. 2009;27(2):95–112.PubMedCrossRef

23.

Dworkin RH, Malone DC, Panarites CJ, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain. 2010;11(4):360–8.PubMedCrossRef

24.

Hall GC, Carroll D, Parry D, et al. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006;122(1–2):156–62.PubMedCrossRef

25.

Dieleman JP, Kerklaan J, Huygen FJ, et al. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain. 2008;137(3):681–8.PubMedCrossRef

26.

Koopman JS, Dieleman JP, Huygen FJ, et al. Incidence of facial pain in the general population. Pain. 2009;147(1–3):122–7.PubMedCrossRef

27.

Ji JS, Chen YJ, Lin MW, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol. 2009;89(6):612–6.CrossRef

28.

Pierik JG, Gumbs PD, Fortanier SA, et al. Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect Dis. 2012; 12:110.

29.

American Geriatrics Society Panel. Pharmacological management of persistent pain in older persons. Pain Med. 2009;10(6):1062–83.CrossRef

30.

Bruckenthal P, Reid MC, Reisner L. Special issues in the management of chronic pain in older adults. Pain Med. 2009;10(S2):S67–78.PubMedCrossRef

31.

Fine PG. Treatment guidelines for the pharmacological management of pain in older persons. Pain Med. 2012;13(Suppl 2):S57–66.PubMedCrossRef

32.

Abdulla A, Adams N, Bone M, et al. Guidance on the management of pain in older people. Age Aging. 2013;42(2):i1–57.CrossRef

33.

Attal N, Cruccu G, Baron R, et al. EFNS Guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–23.PubMedCrossRef

34.

Dworkin RH, O’Conner AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(Suppl 3):S3–14.PubMedCentralPubMedCrossRef

35.

Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573–81.PubMedCrossRef

36.

Magrinelli F, Zanette G, Tamburin S. Neuropathic pain: diagnosis and treatment. Pract Neurol. 2013;13(5):292–307.PubMedCrossRef

37.

Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract. 2014;68(7):900–18.PubMedCrossRef

38.

Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. 2014;14(2):167–84.PubMedCrossRef

39.

Crucca G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;71(15):1183–90.

40.

Zakrzewska JM. Medical management of trigeminal neuropathic pains. Expert Opin Pharmacother. 2010;11(8):1239–54.PubMedCrossRef

41.

Schmader KE, Baron R, Haanpää ML, et al. Treatment considerations for elderly and frail patients with neuropathic pain. Mayo Clin Proc. 2010;83(3 suppl):S26–32.CrossRef

42.

Haanpää ML, Gourlay GK, Kent JL, et al. Treatment considerations for patients with neuropathic pain and other medical comorbidities. Mayo Clin Proc. 2010;85(3 suppl):S15–25.PubMedCentralPubMedCrossRef

43.

O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122(10 Suppl):S22–32.PubMedCrossRef

44.

Chaparro LE, Wiffen PJ, Moore RA, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012; (7):CD008943.

45.

Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurol. 2013;12(11):1084–95.PubMedCrossRef

46.

Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The COMBO-DN study—a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616–25.PubMedCrossRef

47.

Davies PS, Galer BS. Review of lidocaine patch 5 % studies in the treatment of postherpetic neuralgia. Drugs. 2004;64(9):937–47.PubMedCrossRef

48.

Garnock-Jones KP, Keating GM. Lidocaine 5 % medicated plaster. A review of use in postherpetic neuralgia. Drugs. 2009;69(15):2149–65.PubMedCrossRef

49.

Mick G, Correa-Illanes G. Topical pain management with the 5 % lidocaine medicated plaster—a review. Curr Med Res Opin. 2012;28(6):937–51.PubMedCrossRef

50.

Correa-Illanes G, Rao R, Pineros JL, et al. Use of 5 % lidocaine medicated plaster to treat localized neuropathic pain secondary to traumatic injury of peripheral nerves. Local Reg Anesth. 2012;5:47–53.PubMedCentralPubMed

51.

Likar R, Kager I, Obmann M, et al. Treatment of localized neuropathic pain after disk herniation with 5 % lidocaine medicated plaster. Int J Gen Med. 2012;5:689–92.PubMedCentralPubMedCrossRef

52.

Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5 % effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain. 2002;18(5):297–301.PubMedCrossRef

53.

Katz NP, Gammaitoni AR, Davis MW, Lidoderm Patch Study Group, et al. Lidocaine patch 5 % reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med. 2002;3(4):324–32.PubMedCrossRef

54.

Binder A, Bruxelle J, Rogers P, et al. Topical 5 % lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia. Results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Res. 2009;29(6):393–408.

55.

Baron R, Mayoral V, Leijon G, et al. 5 % Lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25(7):1663–76.PubMedCrossRef

56.

Mick G, Baron R, Finnerup NB, et al. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag. 2012;2(1):71–7.PubMedCrossRef

57.

Kern KU, Nalamachu S, Brasseur L, et al. Can treatment success with 5 % lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain? J Pain Res. 2013;6:261–80.PubMedCentralPubMedCrossRef

58.

Casale R, Mattia C. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: focus on 5 % lidocaine-medicated plaster. Ther Clin Risk Manag. 2014;10:259–68.PubMedCentralPubMedCrossRef

59.

Nalamachu S, Wieman M, Bednarek L, et al. Influence of anatomic location of lidocaine patch 5 % on effectiveness and tolerability for postherpetic neuralgia. Patient Prefer Adherence. 2013;7:551–7.PubMedCentralPubMed

60.

Wilhelm IR, Tzabazis A, Likar R, et al. Long-term treatment of neuropathic pain with a 5 % lidocaine medicated plaster. Eur J Anaesthesiol. 2010;27(2):169–73.PubMedCrossRef

61.

Sabatowski R, Hans G, Tacken I, et al. Safety and efficacy outcomes of long-term treatment up to 4 years with 5 % lidocaine medicated plaster in patients with post-herpetic neuralgia. Curr Med Res Opin. 2012;28(8):1337–46.PubMedCrossRef

62.

Wolff RF, Bala MM, Westwood M, et al. 5 % lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol Scand. 2011;123(5):295–309.PubMedCrossRef

63.

Liedegens H, Obradovic M, Nuijten M. Health economic evidence of 5 % lidocaine medicated plaster in post-herpetic neuralgia. Clinicoecon Outcomes Res. 2013;5:597–609.CrossRef

64.

Woulff RF, Bala MM, Westwood M, et al. 5 % lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly. 2010;140(21–22):297–306.

65.

Clère F, Delorme-Morin C, George B, et al. 5 % lidocaine medicated plaster in elderly patients with postherpetic neuralgia. Results of a compassionate use programme in France. Drugs Aging. 2011;28(9):693–702.PubMedCrossRef

66.

Delorme C, Navez ML, Legout V, et al. Treatment of neuropathic pain with 5 % lidocaine-medicated plaster: five years of clinical experience. Pain Res Manag. 2011;16(4):259–63.PubMedCentralPubMed

67.

Pickering G, Pereira B, Clère F, et al. Cognitive function in older patients with postherpetic neuralgia. Pain Pract. 2014;14(1):E1–7.PubMedCrossRef

68.

Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of combination therapy with 5 % lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic neuropathy. Curr Med Res Opin. 2009;25(7):1677–87.PubMedCrossRef

69.

Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8 % patch. Br J Anaesth. 2011;107(4):490–502.PubMedCentralPubMedCrossRef

70.

Haanpää M, Treede RD. Capsaicin for neuropathic pain: linking traditional medicine and molecular biology. Eur Neurol. 2012;68(5):264–75.PubMedCrossRef

71.

Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2012 (9):CD010111. doi:10.1002/14651858.CD010111.

72.

Baranidharan G, Das S, Bhaskar A. A review of the high-concentration capsaicin patch and experience of its use in the management of neuropathic pain. Ther Adv Neurol Disord. 2013;6(5):287–97.PubMedCentralPubMedCrossRef

73.

Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind study. Lancet Neurol. 2008;7(12):1106–12.PubMedCrossRef

74.

Backonja M, Malan TP, Vanouve GF, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11(4):600–8.PubMedCrossRef

75.

Webster LR, Malan TP, Tuchman MM, et al. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch for the treatment of postherpetic neuralgia. J Pain. 2010;11(10):972–82.PubMedCrossRef

76.

Irving GA, Backonjka MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12(1):99–109.PubMedCrossRef

77.

Mou J, Paillard F, Turnbull B, et al. Efficacy of Qutenza^® (capsaicin) 8 % patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials database. Pain. 2013;154(9):1632–9.PubMedCrossRef

78.

Mou J, Paillard F, Turnbull B, et al. Qutenza (capsaicin) 8 % patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. Clin J Pain. 2014;30(4):286–94.PubMedCrossRef

79.

Peppin JF, Majors K, Webster LR, et al. Tolerability of NGX-4010, a capsaicin 8 % patch for peripheral neuropathic pain. J Pain Res. 2011;4:385–92.PubMedCentralPubMedCrossRef

80.

Treede RD, Wagner T, Kern KU, et al. Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8 % cutaneous patch in patients with localized neuropathic pain. Curr Med Res Opin. 2013;29(5):527–38.PubMedCrossRef

81.

Wagner T, Poole C, Roth-Daniek A. The capsaicin 8 % patch for neuropathic pain in clinical practice: a retrospective analysis. Pain Med. 2013;14(8):1202–11.PubMedCentralPubMedCrossRef

82.

Wagner T, Roth-Daniek A, Sell A, et al. Capsaicin 8 % patch for peripheral neuropathic pain: review of treatment best practice from “real-world” clinical experience. Pain Manag. 2012;2(3):239–50.PubMedCrossRef

83.

Kern KU, Nowak W, Poole C. Treatment of neuropathic pain with the capsaicin 8 % patch: is pretreatment with lidocaine necessary? Pain Pract. 2014;14(2):E42–50.PubMedCrossRef

84.

Kern KU, England J, Roth-Daniek A, et al. Is physician supervision of the capsaicin 8 % patch administration procedure really necessary? An opinion from health care professionals. J Pain Res. 2013;6:571–5.PubMedCentralPubMedCrossRef

85.

Armstrong EP, Malone DC, McCarberg B, et al. Cost-effectiveness analysis of a new 8 % capsaicin patch compared to existing therapies for postherpetic neuralgia. Curr Med Res Opin. 2011;27(5):939–50.PubMedCrossRef

86.

Irving GA, Backonja M, Rauck R, et al. NGX-4010, a capsaicin 8 % dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain. 2012;28(8):101–7.PubMedCrossRef

87.

Sawynok J. Topical and peripheral ketamine as an analgesic. Anesth Analg. 2014;119(1):170–8.PubMedCrossRef

88.

Kopsky DJ, Keppel Hesselink JM, Bhaskar A, et al. Analgesic effects of topical Ketamine. Minerva Anesthesiol. 2014 [ePub ahead of print].

89.

Barton DL, Wos EJ, Qin R, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19(6):833–41.PubMedCentralPubMedCrossRef

90.

Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153(9):1815–23.PubMedCentralPubMedCrossRef

91.

Gewandter JS, Mobile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer. 2014;22(7):1807–14.PubMedCentralPubMedCrossRef

92.

NCT00475904 http://www.clinicaltrials.gov.

93.

NCT00476151 http://www.clinicaltrials.gov.

94.

Heir G, Karolchek S, Kalladka M, et al. Use of topical medication in orofacial neuropathic pain: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(4):466–9.PubMedCrossRef

95.

Poterucha TJ, Murphy SL, Rho RH, et al. Topical amitriptyline-ketamine for treatment of rectal, genital, and perineal pain and discomfort. Pain Phys. 2012;15(6):485–8.

96.

Poterucha TJ, Murphy SL, Rho RH, et al. Topical amitriptyline combined with topical ketamine for the management of recalcitrant localized pruritis: a retrospective pilot study. J Am Acad Dermatol. 2013;69(2):320–1.PubMedCrossRef

97.

Poterucha TJ, Murphy SL, Davis MDP, et al. Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: a retrospective study of 36 patients at Mayo Clinic. J Drugs Dermatol. 2013;12(3):308–10.PubMed

98.

Tam E, Furlan AD. Transdermal lidocaine and ketamine for neuropathic pain: a study of effectiveness and tolerability. Open Neurol J. 2012;6:58–64.PubMedCentralPubMedCrossRef

99.

Nasri-Heir C, Khan J, Heir GM. Topical medications as treatment of neuropathic orofacial pain. Dent Clin N Am. 2013;57(3):541–53.PubMedCrossRef

100.

Lynch ME, Clark AJ, Sawynok J, Sullivan MJL. Topical 2 % amitriptyline and 1 % ketamine in neuropathic pain syndromes. A randomized, double-blind, placebo-controlled trial. Anesthesiology. 2005;103(1):140–6.PubMedCrossRef

101.

Mahoney JM, Vardaxis V, Moore JL, et al. Topical ketamine cream in the treatment of painful diabetic neuropathy. A randomized, placebo-controlled, double-blind initial study. J Am Podiatr Med Assoc. 2012;102(3):178–83.PubMedCrossRef

102.

De Barros GAM, Miot HA, Braz AM, et al. Topical (S)-ketamine for pain management of postherpetic neuralgia. An Bras Dermatol. 2012;87(3):504–6.PubMedCrossRef

103.

Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine. Pain. 2009;146(1–2):18–25.PubMedCrossRef

104.

Lockhart E. Topical combination of amitriptyline and ketamine for post-herpetic neuralgia. J Pain. 2004;5:S82.CrossRef

105.

Rowbotham MC, Gilron I, Glazer C, et al. Can pragmatic trials help us better understand chronic pain and improve treatment? Pain. 2013;154(5):643–6.PubMedCrossRef

106.

Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ. 2013;347:f7339.PubMedCrossRef

107.

Moore A, Derry S, Eccelston C, et al. Expect analgesic failure; pursue analgesic success. BMJ. 2013;346:f2690.PubMedCrossRef

Titel: Topical Analgesics for Neuropathic Pain in the Elderly: Current and Future Prospects
verfasst von: Jana Sawynok
Publikationsdatum: 01.12.2014
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 12/2014
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-014-0218-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Topical Analgesics for Neuropathic Pain in the Elderly: Current and Future Prospects

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2014

Medication-Related Fall Incidents in an Older, Ambulant Population: The B-PROOF Study

Effective Pain Management in Patients with Dementia: Benefits Beyond Pain?

Acknowledgement to Referees

Pharmacotherapy for Hypertension in Older Adults: A Systematic Review

Lithium Dosing and Serum Concentrations Across the Age Spectrum: From Early Adulthood to the Tenth Decade of Life

Prevalence of Self-Medication and Associated Factors in an Elderly Population: A Systematic Review

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin